(NASDAQ: CDTX) Cidara Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.2%.
Cidara Therapeutics's earnings in 2025 is -$169,827,000.On average, 1 Wall Street analyst forecast CDTX's earnings for 2025 to be -$77,988,849, with the lowest CDTX earnings forecast at -$77,988,849, and the highest CDTX earnings forecast at -$77,988,849. On average, 1 Wall Street analyst forecast CDTX's earnings for 2026 to be -$160,359,094, with the lowest CDTX earnings forecast at -$160,359,094, and the highest CDTX earnings forecast at -$160,359,094.
In 2027, CDTX is forecast to generate -$182,485,143 in earnings, with the lowest earnings forecast at -$182,485,143 and the highest earnings forecast at -$182,485,143.